Skip to main content Accessibility help
×
Home
Hostname: page-component-54cdcc668b-g2z8v Total loading time: 0.328 Render date: 2021-03-08T17:12:25.242Z Has data issue: false Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Cerebrospinal Fluid IL-21 Levels in Neuromyelitis Optica and Multiple Sclerosis

Published online by Cambridge University Press:  02 December 2014

Aimin Wu
Affiliation:
Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
Xiaonan Zhong
Affiliation:
Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
Honghao Wang
Affiliation:
Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
Wen Xu
Affiliation:
Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
Chen Cheng
Affiliation:
Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
Yongqiang Dai
Affiliation:
Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
Jian Bao
Affiliation:
Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
Wei Qiu
Affiliation:
Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
Zhengqi Lu
Affiliation:
Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
Xueqiang Hu
Affiliation:
Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
Corresponding
Rights & Permissions[Opens in a new window]

Abstract

Background:

Neuromyelitis optica (NMO) and multiple sclerosis (MS) are inflammatory demyelinating diseases of human central nervous system (CNS) with complex pathogenesis. IL-21/IL-21R regulates activation, proliferation and survival of both T cells and B cells, which are involved in the pathogenesis of NMO and MS. High levels of serum IL-21 were observed in NMO patients. However, concentration of cerebrospinal fluid (CSF) IL-21 in MS and NMO patients still remain unknown.

Object:

To detect the CSF concentration of IL-21 in NMO and MS patients and to evaluate its relationship with disease activity, particularly concerned about its impact on humoral immunity.

Methods:

CSF IL-21 was detected by an enzyme-linked immunosorbent assay (ELISA) in NMO patients (n=21), MS patients (n=20) and controls (n=16).

Results:

CSF concentration of the IL-21 was noticeably elevated in NMO (p=0.012) and borderline significantly increased in MS (p=0.115). In addition, this occurrence was associated with humoral immune activity as shown by a correlation between IL-21 and complement in NMO cohort (p=0.023) and high IL-21 levels in autoantibody-positive subgroup (p=0.027).

Conclusions:

The concentration of CSF IL-21 was noticeably elevated and might have a positive correlation with humoral immune activity in NMO.

Résumé

RÉSUMÉ Contexte:

La neuromyélite optique (NMO) et la sclérose en plaques (SP) sont des maladies démyélinisantes inflammatoires du système nerveux central (SNC) humain dont la pathogenèse est complexe. IL-21/IL-21R régule l'activation, la prolifération et la survie des cellules T et des cellules B qui sont impliquées dans la pathogenèse de la NMO et de la SP. Des taux sériques élevés d'IL-21 ont été observés chez des patients atteints de NMO. Cependant, la concentration d'IL-21 dans le liquide céphalo-rachidien (LCR) de patients atteints de SP ou de NMO demeure inconnue.

Objectif:

Le but de l'étude était de déterminer la concentration d'IL-21 dans le LCR de patients atteints de NMO ou de SP et d'évaluer sa relation à l'activité de la maladie, particulièrement en ce qui a trait à son impact sur l'activité immunitaire humorale.

Méthode:

L'IL-21 dans le LCR a été identifié par ELISA chez 21 patients atteints de NMO, 20 patients atteints de SP et 16 sujets témoins.

Résultats:

La concentration d'IL-21 dans le LCR était sensiblement élevée chez les patients atteints de NMO (p = 0,012) et limite chez les patients atteints de SP (p = 0,115). De plus, ceci était associé à une activité immunitaire humorale comme le démontre la corrélation entre IL-21 et le complément dans la cohorte de patients atteints de NMO (p = 0,023) et un niveau élevé d'IL-21 dans le sous-groupe de patients possédant des autoanticorps (p = 0,027).

Conclusions:

La concentration d'IL-21 dans le LCR était sensiblement élevée chez les patients atteints de NMO et pourrait avoir une corrélation positive avec l'activité immunitaire humorale.

Type
Original Articles
Copyright
Copyright © The Canadian Journal of Neurological 2012

References

1. Matà, S, Lolli, F. Neuromyelitis optica: an update. J Neurol Sci. 2011;303(1–2):1321.CrossRefGoogle ScholarPubMed
2. Fletcher, JM, Lalor, SJ, Sweeney, CM, et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010;162(1):111.CrossRefGoogle ScholarPubMed
3. Li, Y, Wang, H, Long, Y, et al. Increased memory Th17cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2011;234(1–2):15560.CrossRefGoogle Scholar
4. Link, H, Tibbling, G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest. 1977;37(5):397401.CrossRefGoogle Scholar
5. Archelos, JJ, Storch, MK, Hartung, HP. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol. 2000;47(6): 694706.3.0.CO;2-W>CrossRefGoogle Scholar
6. Lennon, V.A, Wingerchuk, DM, Kryzer, TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):210612.CrossRefGoogle Scholar
7. Watanabe, S, Nakashima, I, Misu, T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007;13(1):12832.CrossRefGoogle ScholarPubMed
8. Bakker, J, Metz, L. Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci. 2004;31 (2):2657.CrossRefGoogle Scholar
9. Cree, BA, Lamb, S, Morgan, K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64 (7):12702.CrossRefGoogle ScholarPubMed
10. Bedi, GS, Brown, AD, Delgado, SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17(10):122530.CrossRefGoogle ScholarPubMed
11. Pellkofer, HL, Krumbholz, M, Berthele, A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):13105.CrossRefGoogle ScholarPubMed
12. Ozaki, K, Kikly, K, Michalovich, D, et al. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA. 2000;97(21):1143944.CrossRefGoogle Scholar
13. Parrish-Novak, J, Dillon, SR, Nelson, A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408(6808):5763.Google Scholar
14. Spolski, R, Leonard, WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol. 2008:26:5779.CrossRefGoogle ScholarPubMed
15. Monteleone, G, Caruso, R, Fina, D, et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut. 2006;55(12):177480.CrossRefGoogle ScholarPubMed
16. Monteleone, G, Pallone, F, Macdonald, TT. Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci. 2009;30(8):4417.CrossRefGoogle ScholarPubMed
17. Deenick, EK, Tangye, SG. Autoimmunity: IL-21: a new player in Th17-cell differentiation. Immunol Cell Biol. 2007;85(7):5035.CrossRefGoogle ScholarPubMed
18. Monteleone, G, Pallone, F, Macdonald, TT. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev. 2009;20(2):18591.CrossRefGoogle ScholarPubMed
19. Konforte, D, Simard, N, Paige, CJ. IL-21: an executor of B cell fate. J Immunol 2009;182(4):17817.CrossRefGoogle Scholar
20. Ettinger, R, Kuchen, S, Lipsky, PE. Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis. 2008;67 Suppl 3:iii836.CrossRefGoogle ScholarPubMed
21. Ettinger, R, Kuchen, S, Lipsky, PE. The role of IL-21 inregulating B-cell functionin health and disease. Immunol Rev. 2008;223: 6086.CrossRefGoogle Scholar
22. Wang, HH, Dai, YQ, Qiu, W, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci. 2011;18(10):13137.CrossRefGoogle Scholar
23. Wingerchuk, DM, Lennon, VA, Pittock, SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10): 14859.CrossRefGoogle Scholar
24. Polman, CH, Reingold, SC, Banwell, B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292302.CrossRefGoogle ScholarPubMed
25. Vollmer, TL, Liu, R, Price, M, et al. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol. 2005;174(5):2696701.CrossRefGoogle ScholarPubMed
26. Chen, M, Chen, G, Nie, H, et al. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. Eur J Immunol. 2009;39(9):252536.CrossRefGoogle ScholarPubMed
27. Zhang, X, Tao, Y, Troiani, L, et al. Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. J Immunol. 2011;187(6):34317.CrossRefGoogle Scholar
28. Xie, L, Li, XK, Funeshima-Fuji, N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol. 2009;9(5):57581.CrossRefGoogle Scholar
29. Andersson, A, Isaksson, M, Wefer, J, et al. Impaired autoimmune T helper 17 cell responses following DNA vaccination against rat experimental autoimmune encephalomyelitis. PLoS One. 2008;3(11):e3682.CrossRefGoogle Scholar
30. Kwok, SK, Cho, ML, Park, MK, et al. Interleukin-21 promotes osteoclasto genesis in rheumatoid arthritis in humans and mice. Arthritis Rheum. 2012;64(3):74051 CrossRefGoogle Scholar
31. Kang, KY, Kim, HO, Kwok, SK, et al. Impact of interleukin-21 in the pathogenesis of primary Sjogren’s syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther. 2011;13(5):R179.CrossRefGoogle ScholarPubMed
32. Tüzün, E, Kürtüncü, M, Türkoğlu, R, et al. Enhanced complement consumption in neuromyelitis optica and Behçet’s disease patients. J Neuroimmunol. 2011;233(–1–2):2115.CrossRefGoogle ScholarPubMed
33. Doi, H, Matsushita, T, Isobe, N, et al. Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody. Mult Scler. 2009;15(3):30410.CrossRefGoogle ScholarPubMed
34. Bradl, M, Misu, T, Takahashi, T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66(5):63043.CrossRefGoogle ScholarPubMed
35. Jarius, S, Paul, F, Franciotta, D, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008;4(4): 20214.Google Scholar
36. Fedetz, M, Ndagire, D, Fernandez, O, et al. Multiple sclerosis association study with the TENR-IL2-IL21 region in a Spanish population. Tissue Antigens. 2009;74(3):2447.CrossRefGoogle Scholar
37. Lindén, M, Nohra, R, Sundqvist, E, et al. No evidence of IL21 association with multiple sclerosis in a Swedish population. Tissue Antigens. 2011;78(4):2714.CrossRefGoogle Scholar
38. Tzartos, JS, Craner, MJ, Friese, MA, et al. IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am J Pathol. 2011;178(2):794802.CrossRefGoogle ScholarPubMed

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 0
Total number of PDF views: 190 *
View data table for this chart

* Views captured on Cambridge Core between September 2016 - 8th March 2021. This data will be updated every 24 hours.

Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Cerebrospinal Fluid IL-21 Levels in Neuromyelitis Optica and Multiple Sclerosis
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Cerebrospinal Fluid IL-21 Levels in Neuromyelitis Optica and Multiple Sclerosis
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Cerebrospinal Fluid IL-21 Levels in Neuromyelitis Optica and Multiple Sclerosis
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *